PRIMAQUINE 15 TAB is a therapeutic antimalarial agent containing Primaquine Phosphate 15 mg, a synthetic 8-aminoquinoline compound that is uniquely effective in targeting the hepatic (liver) stages and gametocytes of malaria parasites. It is primarily used for the radical cure of Plasmodium vivax and Plasmodium ovale infections by eliminating hypnozoites—the dormant liver forms of the parasite responsible for relapses. This sets Primaquine apart from most other antimalarials, which only target the blood-stage parasites.

This formulation is also instrumental in blocking malaria transmission by destroying the sexual forms (gametocytes) of Plasmodium falciparum, thereby reducing the spread of the disease in endemic communities. PRIMAQUINE 15 TAB is often administered in conjunction with other antimalarial drugs such as chloroquine or artemisinin-based combination therapies (ACTs) to ensure comprehensive parasite clearance.

The pharmacodynamics of Primaquine involve interference with mitochondrial electron transport and oxidative stress in parasitic cells. While the exact mechanism of action remains partially understood, its clinical efficacy in preventing malaria relapse has been well-established through decades of use.

PRIMAQUINE 15 TAB is typically administered once daily for 14 days in standard treatment regimens. The duration and dosing may vary based on body weight, patient age, G6PD enzyme status, and the regional resistance pattern. Because of its potential for inducing hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, G6PD testing is strongly recommended before initiation of therapy. In G6PD-deficient individuals, alternative regimens or careful monitoring may be necessary to avoid adverse effects.

Common side effects of Primaquine include gastrointestinal discomfort, such as nausea and abdominal cramps, as well as transient methemoglobinemia. Severe side effects like hemolytic anemia and leukopenia are rare but clinically significant, particularly in patients with underlying red blood cell disorders. As such, patient screening and clinical supervision are vital to ensuring safe use.

PRIMAQUINE 15 TAB is a critical tool in the World Health Organization's malaria eradication programs, especially in regions where P. vivax remains endemic. Its effectiveness in interrupting the parasite's life cycle at multiple stages makes it indispensable in both therapeutic and prophylactic contexts. Furthermore, it has utility in mass drug administration (MDA) campaigns aimed at interrupting transmission cycles during outbreaks.

Manufactured by Bluepill Express in state-of-the-art WHO-GMP and ISO-certified facilities, PRIMAQUINE 15 TAB meets stringent quality and regulatory requirements. Every batch undergoes rigorous testing for identity, potency, dissolution, and stability to ensure global compliance and safety. The formulation is available for domestic supply, hospital use, government tender programs, and global export across Africa, Asia, South America, and other malaria-prone regions.

PRIMAQUINE 15 TAB is offered as part of Bluepill Express's comprehensive portfolio of antimalarial medicines, with full documentation including Certificate of Analysis (COA), stability studies, product registration dossiers, and GMP certifications to support regulatory submissions in semi-regulated and regulated markets. Custom branding, packaging, and private labeling options are also available for contract manufacturing clients.